A liposomal dispersion formulation of propofol: formulation, pharmacokinetics, stability, and identification of an oxidative degradant

The care and feeding of a commercial liposomal product: liposomal amphotericin B (AmBisome®)

“…Colour was from the SoyPC itself and riboflavin-5 0 -phosphate, both encapsulated and in the buffer, at a low enough doses to avoid observation in the urine. To develop the appropriate opalescence of the $80 nm median diameter AmBisome particle extrusion was used to process the SoyPC liposomes, as high sheer processing typically results in much smaller liposomes for this formulation (Jensen et al 2008). The adverse events profile of the placebo in a recently published clinical trial reflects no evidence of complement activation for this formula (Cornely et al 2017).…”

Nanostructured Lipid Carrier of Propofol: a Promising Alternative to Marketed Soybean Oil–Based Nanoemulsion

“…Numerous attempts have been made so far to overcome these limitations associated with this soybean oil-based nanoemulsion, like reducing the soybean oil content (4); polymeric micelles (11,12); microemulsions using mediumchain triglycerides (MCTs) (1,2,13,14); liposomes (15); complexation with cyclodextrin (16,17); and formation of watersoluble prodrug (Fospropofol) (18). All these developed formulations apparently overcome some of the limitations associated with marketed formulation but are left with some other complications instead.…”